JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

JNJ

192.21

-0.27%↓

ABT

126.36

-1.56%↓

MDT

94.08

-2.31%↓

VEEV

290.31

+0.87%↑

A

147.08

+0.55%↑

Search

Alkermes PLC

Open

SectorGezondheidszorg

30.16 -3.86

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.88

Max

31.32

Belangrijke statistieken

By Trading Economics

Inkomsten

65M

87M

Verkoop

84M

391M

K/W

Sectorgemiddelde

14.613

37.461

Winstmarge

22.295

Werknemers

1,800

EBITDA

99M

113M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+29.09% upside

Dividenden

By Dow Jones

Volgende Winsten

28 okt 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

802M

5.1B

Vorige openingsprijs

34.02

Vorige sluitingsprijs

30.16

Nieuwssentiment

By Acuity

50%

50%

168 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Alkermes PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

22 okt 2025, 22:47 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22 okt 2025, 22:13 UTC

Acquisities, Fusies, Overnames

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22 okt 2025, 21:20 UTC

Winsten

Correction to IBM 3Q Sales Jump Article

22 okt 2025, 20:57 UTC

Winsten

SAP Posts Higher 3Q Revenue, Operating Profit

22 okt 2025, 23:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

22 okt 2025, 23:46 UTC

Marktinformatie

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22 okt 2025, 23:41 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:38 UTC

Marktinformatie

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22 okt 2025, 23:15 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22 okt 2025, 22:28 UTC

Marktinformatie

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22 okt 2025, 22:02 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22 okt 2025, 21:59 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22 okt 2025, 21:58 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22 okt 2025, 21:57 UTC

Acquisities, Fusies, Overnames

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22 okt 2025, 21:56 UTC

Acquisities, Fusies, Overnames

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22 okt 2025, 21:47 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 21:47 UTC

Acquisities, Fusies, Overnames

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22 okt 2025, 21:46 UTC

Acquisities, Fusies, Overnames

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22 okt 2025, 21:45 UTC

Acquisities, Fusies, Overnames

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22 okt 2025, 21:28 UTC

Marktinformatie
Winsten

Correction to Alcoa Tariff Market Talk

22 okt 2025, 21:25 UTC

Winsten

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22 okt 2025, 21:17 UTC

Winsten

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22 okt 2025, 21:09 UTC

Marktinformatie
Winsten

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22 okt 2025, 21:00 UTC

Marktinformatie

ESG Roundup: Market Talk

22 okt 2025, 20:59 UTC

Winsten

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22 okt 2025, 20:51 UTC

Winsten

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

22 okt 2025, 20:44 UTC

Winsten

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer Vergelijking

Prijswijziging

Alkermes PLC Prognose

Koersdoel

By TipRanks

29.09% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.6 USD  29.09%

Hoogste 47 USD

Laagste 33 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Alkermes PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

7

Buy

4

Hold

0

Sell

Technische score

By Trading Central

27.95 / 30.91Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

168 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat